{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:37Z","timestamp":1792425637965,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Given the high prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe adverse hepatic outcomes, risk stratification for patients with MASLD is crucial. Notably, cardiovascular disease (CVD) represents the leading cause of mortality in this population. High-sensitivity troponin (hs-troponin) is a well-established biomarker of subclinical myocardial injury and predicts cardiovascular outcomes. However, its specific relationship with advanced liver fibrosis (ALF) in MASLD remains unexplored. Therefore, we investigated this association in individuals with MASLD without CVD. We analyzed data from 4684 adults aged \u226518 years in the 1999 to 2004 National Health and Nutrition Examination Survey. Multivariable logistic regression examined associations between hs-troponin and ALF. Diagnostic utility was assessed using receiver operating characteristic curve analysis. Moreover, we conducted a mediation analysis to explore the role of inflammation, as represented by the monocyte-to-lymphocyte ratio, in the aforementioned association. Among 4684 patients without CVD, 169 had ALF. After controlling for confounding factors, hs-troponin T showed a significant positive association with ALF (adjusted odds ratio: 1.02, 95% confidence interval: 1.01\u20131.03,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.020). Additionally, receiver operating characteristic analysis indicated that at a cutoff of 7.28\u2009ng\/L, hs-troponin T predicted ALF with an area under the curve of 0.85 (95% confidence interval: 0.82\u20130.88). Further mediation analysis revealed that inflammation partially mediated the association between hs-troponin T and ALF. Our findings indicate that elevated hs-troponin T is independently associated with a higher risk of ALF, which can assist clinicians in risk stratification for this population. These findings suggest that hs-troponin T, a marker of subclinical cardiovascular stress, may also serve as a practical tool for hepatic risk stratification.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049537","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:01:00Z","timestamp":1783098060000},"page":"e49537","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Association of high-sensitivity troponin with advanced fibrosis in metabolic dysfunction-associated steatotic liver disease and the potential mediating role of inflammation: A cross-sectional study of NHANES, 1999 to 2004"],"prefix":"10.1097","volume":"105","author":[{"given":"Chun Yu","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Guangdong Provincial People\u2019s Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Xiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Guangdong Provincial People\u2019s Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University, Taizhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0122-6995","authenticated-orcid":false,"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University, Taizhou, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD.","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"R2-20260709","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: an immunometabolic perspective.","volume":"20","author":"Schwarzler","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"R3-20260709","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","article-title":"Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.","volume":"29","author":"Konyn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl19069","article-title":"Extrahepatic manifestations of nonalcoholic fatty liver disease.","volume":"14","author":"Li","year":"2020","journal-title":"Gut Liver"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/clinchem\/hvac092","article-title":"Analytical considerations in deriving 99th percentile upper reference limits for high-sensitivity cardiac troponin assays: educational recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers.","volume":"68","author":"Aakre","year":"2022","journal-title":"Clin Chem"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehad328","article-title":"High-sensitivity troponins and mortality in the general population.","volume":"44","author":"McEvoy","year":"2023","journal-title":"Eur Heart J"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/eurheartj\/ehs163","article-title":"High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate.","volume":"33","author":"Scheven","year":"2012","journal-title":"Eur Heart J"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","article-title":"Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial (Examination of Cardiovascular Outcomes with Alogliptin Versus Standard of Care).","volume":"135","author":"Cavender","year":"2017","journal-title":"Circulation"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/apt.70128","article-title":"Association of high-sensitivity troponins in metabolic dysfunction-associated steatotic liver disease with all-cause and cause-specific mortality.","volume":"61","author":"Kim","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-20260709","doi-asserted-by":"crossref","first-page":"19541","DOI":"10.1038\/s41598-024-70645-7","article-title":"High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease.","volume":"14","author":"Hu","year":"2024","journal-title":"Sci Rep"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1111\/liv.12428","article-title":"Cardiac and proinflammatory markers predict prognosis in cirrhosis.","volume":"34","author":"Wiese","year":"2014","journal-title":"Liver Int"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10741-025-10500-7","article-title":"Cirrhotic cardiomyopathy: comprehensive insights into pathophysiology, diagnosis, and management.","volume":"30","author":"Ndakotsu","year":"2025","journal-title":"Heart Fail Rev"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-)associated steatotic liver disease and risk of cardiovascular disease.","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach.","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"102910","DOI":"10.1016\/j.redox.2023.102910","article-title":"Associations of essential trace elements with epigenetic aging indicators and the potential mediating role of inflammation.","volume":"67","author":"Cheng","year":"2023","journal-title":"Redox Biol"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis.","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R18-20260709","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/0886022X.2012.656562","article-title":"Increased cardiac troponin T levels are related to inflammatory markers and various indices of renal function in chronic renal disease patients.","volume":"34","author":"Sezer","year":"2012","journal-title":"Ren Fail"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"5525917","DOI":"10.1155\/2021\/5525917","article-title":"The inflammasome signaling pathway is actively regulated and related to myocardial damage in coronary thrombi from patients with STEMI.","volume":"2021","author":"Nordeng","year":"2021","journal-title":"Mediators Inflamm"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic Steatosis Index: a simple screening tool reflecting nonalcoholic fatty liver disease.","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/hep.31158","article-title":"Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease.","volume":"72","author":"Kim","year":"2020","journal-title":"Hepatology"},{"key":"R22-20260709","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R23-20260709","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/hepr.13737","article-title":"Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.","volume":"52","author":"Park","year":"2022","journal-title":"Hepatol Res"},{"key":"R24-20260709","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"R25-20260709","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2023.03.403","article-title":"Myocardial injury thresholds for 4 high-sensitivity troponin assays in U.S. adults.","volume":"81","author":"McEvoy","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13098-025-01640-9","article-title":"Association between monocyte-to-lymphocyte ratio and cardiovascular diseases: insights from NHANES data.","volume":"17","author":"Li","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1161\/CIRCULATIONAHA.105.609974","article-title":"Prevalence and determinants of troponin T elevation in the general population.","volume":"113","author":"Wallace","year":"2006","journal-title":"Circulation"},{"key":"R29-20260709","doi-asserted-by":"crossref","first-page":"e005930","DOI":"10.1161\/JAHA.117.005930","article-title":"Role of admission troponin-T and serial troponin-T testing in predicting outcomes in severe sepsis and septic shock.","volume":"6","author":"Vallabhajosyula","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/CIRCULATIONAHA.110.005264","article-title":"Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.","volume":"123","author":"Saunders","year":"2011","journal-title":"Circulation"},{"key":"R31-20260709","doi-asserted-by":"crossref","first-page":"100631","DOI":"10.1016\/j.ajpc.2023.100631","article-title":"Four high sensitivity troponin assays and mortality in US adults with cardiovascular disease: the National Health and Nutrition Examination Survey, 1999\u20132004.","volume":"17","author":"McEvoy","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"R32-20260709","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","article-title":"Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association.","volume":"42","author":"Duell","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R33-20260709","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.2011.01369.x","article-title":"Resistin: functional roles and therapeutic considerations for cardiovascular disease.","volume":"165","author":"Jamaluddin","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R34-20260709","doi-asserted-by":"crossref","first-page":"110688","DOI":"10.1016\/j.clinbiochem.2023.110688","article-title":"The liver-heart axis in patients with severe obesity: the association between liver fibrosis and chronic myocardial injury may be explained by shared risk factors of cardiovascular disease.","volume":"123","author":"Young","year":"2024","journal-title":"Clin Biochem"},{"key":"R35-20260709","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association.","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"R36-20260709","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ehjqcco\/qcab005","article-title":"Estimating the cost-effectiveness of screening a general population for cardiovascular risk with high-sensitivity troponin-I.","volume":"8","author":"Julicher","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"R37-20260709","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:01:58Z","timestamp":1783616518000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000049537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":37,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049537","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}